Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

2.

Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.

Clark JA, Humphries JE, Crean S, Reynolds MW.

Pharmacoepidemiol Drug Saf. 2010 Feb;19(2):107-14. doi: 10.1002/pds.1874. Review.

PMID:
20014051
3.

Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?

Michel C, Scosyrev E, Petrin M, Schmouder R.

Clin Drug Investig. 2017 May;37(5):415-422. doi: 10.1007/s40261-017-0503-6. Review.

PMID:
28224371
4.

Effect of consumer reporting on signal detection: using disproportionality analysis.

Hammond IW, Rich DS, Gibbs TG.

Expert Opin Drug Saf. 2007 Nov;6(6):705-12. Review.

PMID:
17967159
5.

Data mining of the public version of the FDA Adverse Event Reporting System.

Sakaeda T, Tamon A, Kadoyama K, Okuno Y.

Int J Med Sci. 2013 Apr 25;10(7):796-803. doi: 10.7150/ijms.6048. Print 2013. Review.

6.

Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.

Brajovic S, Piazza-Hepp T, Swartz L, Dal Pan G.

Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):565-70; discussion 571-2. doi: 10.1002/pds.3223. Epub 2012 Feb 22. Review.

PMID:
22359404
7.

Quantitative methods in pharmacovigilance: focus on signal detection.

Hauben M, Zhou X.

Drug Saf. 2003;26(3):159-86. Review.

PMID:
12580646
8.

Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices.

Stergiopoulos S, Getz K.

Drug Saf. 2015 Aug;38(8):687-92. doi: 10.1007/s40264-015-0310-z. Review.

PMID:
26108298
9.

Perspectives on the use of data mining in pharmaco-vigilance.

Almenoff J, Tonning JM, Gould AL, Szarfman A, Hauben M, Ouellet-Hellstrom R, Ball R, Hornbuckle K, Walsh L, Yee C, Sacks ST, Yuen N, Patadia V, Blum M, Johnston M, Gerrits C, Seifert H, Lacroix K.

Drug Saf. 2005;28(11):981-1007. Review.

PMID:
16231953
10.

[A review of potential signals generated by an automated method on 3324 pharmacovigilance case reports].

Bousquet C, Sadakhom C, Le Beller C, Jaulen MC, Lillo-Le Lou√ęt A.

Therapie. 2006 Jan-Feb;61(1):39-47. Review. French.

PMID:
16792153
11.

Adverse event monitoring and multivitamin-multimineral dietary supplements.

Woo JJ.

Am J Clin Nutr. 2007 Jan;85(1):323S-324S. Review.

PMID:
17209219
12.

Reporting of deaths during pre-approval clinical trials for advanced HIV-infected populations.

Johann-Liang R, James AN, Behr VL, Struble K, Birnkrant DB.

Drug Saf. 2005;28(7):559-64. Review.

PMID:
15963004
13.

Limitations and strengths of spontaneous reports data.

Goldman SA.

Clin Ther. 1998;20 Suppl C:C40-4. Review.

PMID:
9915089
14.

Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Jaquenoud Sirot E, van der Velden JW, Rentsch K, Eap CB, Baumann P.

Drug Saf. 2006;29(9):735-68. Review.

PMID:
16944962
15.

Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions.

Hauben M, Aronson JK.

Drug Saf. 2009;32(2):99-110. doi: 10.2165/00002018-200932020-00003. Review.

PMID:
19236117
16.

Drug-induced cardiac abnormalities in premature infants and neonates.

Pesco-Koplowitz L, Gintant G, Ward R, Heon D, Saulnier M, Heilbraun J.

Am Heart J. 2018 Jan;195:14-38. doi: 10.1016/j.ahj.2017.07.014. Epub 2017 Jul 31. Review.

PMID:
29224642
17.

Contextualising Water Use in Residential Settings: A Survey of Non-Intrusive Techniques and Approaches.

Carboni D, Gluhak A, McCann JA, Beach TH.

Sensors (Basel). 2016 May 20;16(5). pii: E738. doi: 10.3390/s16050738. Review.

Supplemental Content

Support Center